Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPCRIADO, Paulo RicardoPAGLIARI, CarlaCRIADO, Roberta Fachini JardimMARQUES, Gabriela FrancoJR, Walter Belda2021-02-182021-02-182020DERMATOLOGIC THERAPY, v.33, n.6, article ID e14068, 9p, 20201396-0296https://observatorio.fm.usp.br/handle/OPI/39159Coronavirus disease (COVID-19) pandemic presents several dermatological manifestations described in the present indexed literature, with around 700 cases reported until May 2020, some described as urticaria or urticarial rashes. Urticaria is constituted by evanescent erythematous-edematous lesions (wheals and flare), which does not persist in the same site for more than 24 to 48 hours and appears in other topographic localization, resolving without residual hyper pigmentation. During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, some cytokines are synthesized, including Interferon (IFN) type I, TNF-alpha, and chemokines which may induce mast cells (MCs) and basophils degranulation by mechanisms similar to the autoinflammatory monogenic or polygenic diseases. In this article, we discuss the spectrum of the urticaria and urticarial-like lesions in the COVID-19's era, besides other aspects related to innate and adaptative immune response to viral infections, interactions between dermal dendritic cells and MCs, and degranulation of MCs by different stimuli. Plasmacytoid dendritic cells share, in allergic patients, expression of the high-affinity IgE receptors on cell membranes and demonstrated a low pattern of type I IFN secretion in viral infections. We discuss the previous descriptions of the effects of omalizumab, a monoclonal antibody directed to IgE and high-affinity IgE receptors, to improve the IFN responses and enhance their antiviral effects.engrestrictedAccessCOVID-19dendritic cellsinnate immunitymast cellsSARS-CoV-2urticariadengue virus-infectionimmune-responsesigeasthmarhinoviruscovid-19receptorbasophilscytokinessarsarticleCopyright WILEY10.1111/dth.14068Dermatology1529-8019